Impact Biomedical, Stock Fundamentals
| IBO Stock | USD 1.80 0.05 2.70% |
Impact BioMedical, fundamentals help investors to digest information that contributes to Impact BioMedical,'s financial success or failures. It also enables traders to predict the movement of Impact Stock. The fundamental analysis module provides a way to measure Impact BioMedical,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Impact BioMedical, stock.
As of the 8th of January 2025, Total Other Income Expense Net is likely to grow to about 62.8 K, while Selling General Administrative is likely to drop about 1.1 M. Impact | Select Account or Indicator |
Impact BioMedical, Company Current Valuation Analysis
Impact BioMedical,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Impact BioMedical, Current Valuation | 26.68 M |
Most of Impact BioMedical,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Impact BioMedical, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Impact Current Valuation Historical Pattern
Today, most investors in Impact BioMedical, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Impact BioMedical,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Impact BioMedical, current valuation as a starting point in their analysis.
Impact BioMedical, Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Impact BioMedical, has a Current Valuation of 26.68 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is notably lower than that of the firm.
Impact BioMedical, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Impact BioMedical,'s current stock value. Our valuation model uses many indicators to compare Impact BioMedical, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Impact BioMedical, competition to find correlations between indicators driving Impact BioMedical,'s intrinsic value. More Info.Impact BioMedical, is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . At this time, Impact BioMedical,'s Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Impact BioMedical,'s earnings, one of the primary drivers of an investment's value.Impact Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Impact BioMedical,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Impact BioMedical, could also be used in its relative valuation, which is a method of valuing Impact BioMedical, by comparing valuation metrics of similar companies.Impact BioMedical, is currently under evaluation in current valuation category among its peers.
Impact Fundamentals
| Return On Equity | 0.0345 | ||||
| Return On Asset | -0.0499 | ||||
| Current Valuation | 26.68 M | ||||
| Shares Outstanding | 11.5 M | ||||
| Shares Owned By Insiders | 55.16 % | ||||
| Shares Owned By Institutions | 1.69 % | ||||
| Number Of Shares Shorted | 1.05 K | ||||
| Price To Book | 0.68 X | ||||
| EBITDA | (2.82 M) | ||||
| Net Income | (4.34 M) | ||||
| Total Debt | 12.07 M | ||||
| Book Value Per Share | 2.72 X | ||||
| Cash Flow From Operations | (2.85 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | 0.10 X | ||||
| Market Capitalization | 21.28 M | ||||
| Total Asset | 44.63 M | ||||
| Retained Earnings | (12.96 M) | ||||
| Working Capital | (12.8 M) | ||||
| Net Asset | 44.63 M |
About Impact BioMedical, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Impact BioMedical,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Impact BioMedical, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Impact BioMedical, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.76 | 0.67 | |
| Sales General And Administrative To Revenue | 3.84 | 3.42 | |
| Research And Ddevelopement To Revenue | 0.34 | 0.30 | |
| Capex To Revenue | 0.08 | 0.07 | |
| Ebit Per Revenue | 0.42 | 0.37 |
Pair Trading with Impact BioMedical,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Impact BioMedical, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Impact BioMedical, will appreciate offsetting losses from the drop in the long position's value.Moving against Impact Stock
| 0.57 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.56 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.51 | LLY | Eli Lilly | PairCorr |
The ability to find closely correlated positions to Impact BioMedical, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Impact BioMedical, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Impact BioMedical, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Impact BioMedical, to buy it.
The correlation of Impact BioMedical, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Impact BioMedical, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Impact BioMedical, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Impact BioMedical, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Impact BioMedical, Piotroski F Score and Impact BioMedical, Altman Z Score analysis. To learn how to invest in Impact Stock, please use our How to Invest in Impact BioMedical, guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Impact BioMedical,. If investors know Impact will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Impact BioMedical, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Impact BioMedical, is measured differently than its book value, which is the value of Impact that is recorded on the company's balance sheet. Investors also form their own opinion of Impact BioMedical,'s value that differs from its market value or its book value, called intrinsic value, which is Impact BioMedical,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Impact BioMedical,'s market value can be influenced by many factors that don't directly affect Impact BioMedical,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Impact BioMedical,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Impact BioMedical, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Impact BioMedical,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.